Compare Illumina, Inc. (ILMN) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oatly Group AB - ADR — how do they compare? Illumina, Inc. trades at $278.09 (market cap $39.95B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Illumina, Inc. is far larger — about 120.7× Oatly Group AB - ADR's market cap, and Illumina, Inc. is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Oatly Group AB - ADR for 18 Days on average.
| ILMN | OTLY | |
|---|---|---|
Market Cap | $39.95B | $330.93M |
Volume | 3,169,503 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $293.69 | $15.91 |
52-Week Low | $91.00 | $8.03 |
Typical Hold Time | 83 Days | 18 Days |
Enterprise Value | $41.31B | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
OTLY trades at $10.59, up 2.12% today, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, reflecting margin improvements. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment. However, negative cash flows and high debt-to-asset ratio of 66.53% in 2025 pose risks. Analyst consensus is mixed with a $12.28 price target, indicating modest upside potential from current levels.
Outlook: OTLY shows operational progress with revenue growth and reduced losses, but profitability remains elusive. Investment opportunity hinges on sustained margin expansion and positive EBITDA. Key risks include cash burn, competitive pressures, and leverage. Investors should weigh turnaround potential against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
